Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500
Debt
Debt-to-Equity Ratio0.78
Current Ratio9.92
Quick Ratio9.74
Price-To-Earnings
Trailing P/E Ratio-5.65
Forward P/E Ratio-4.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$570,000.00
Price / Sales1,069.95
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book7.73
Profitability
EPS (Most Recent Fiscal Year)($3.97)
Net Income$-89,490,000.00
Net Margins-1,138.59%
Return on Equity-104.86%
Return on Assets-54.21%
Miscellaneous
Employees147
Outstanding Shares27,190,000
Market Cap$628.10 million
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) issued its quarterly earnings results on Thursday, August, 2nd. The specialty pharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.41) by $0.15. The specialty pharmaceutical company earned $7.57 million during the quarter, compared to the consensus estimate of $4.84 million. Adamas Pharmaceuticals had a negative return on equity of 104.86% and a negative net margin of 1,138.59%. View Adamas Pharmaceuticals' Earnings History.
When is Adamas Pharmaceuticals' next earnings date?
What price target have analysts set for ADMS?
12 brokerages have issued 12-month target prices for Adamas Pharmaceuticals' shares. Their forecasts range from $31.00 to $75.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $46.1111 in the next twelve months. This suggests a possible upside of 105.6% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.
What is the consensus analysts' recommendation for Adamas Pharmaceuticals?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamas Pharmaceuticals.
What are Wall Street analysts saying about Adamas Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We hosted an investor lunch with a practicing neurologist who discussed his experience with Gocovri. Specifically, he reported hallucinations in approximately 50% of his patients, vs. the 21% reported in the product label. This doctor attributed the side effect to rapid titration to the 274 mg daily dose, and has started to experiment with starting patients on the lowest 68.5 mg dose of the product (but was concerned that efficacy was modest at this level). This physician treated ~20 patients so far, but only 5-7 of these currently remain on the drug. We learned that for his patients 65 years had to be stepped down in dose or stop taking the product." (8/17/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We have utilized a discounted cash flow (DCF)-based approach to derive a composite valuation assessment of Adamas, which ascribes value to the company’s two principal product opportunities— GOCOVRI and ADS-5102—while also accounting for the token value provided by the royalty stream from Allergan plc on two other controlled-release products, for treatment of moderate-to-severe Alzheimer’s disease (AD)." (7/16/2018)
- 3. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (5/9/2018)
Are investors shorting Adamas Pharmaceuticals?
Adamas Pharmaceuticals saw a drop in short interest in July. As of July 31st, there was short interest totalling 8,185,393 shares, a drop of 1.4% from the July 13th total of 8,304,743 shares. Based on an average daily trading volume, of 441,378 shares, the days-to-cover ratio is presently 18.5 days. Approximately 38.0% of the shares of the company are short sold. View Adamas Pharmaceuticals' Current Options Chain.
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT), Myokardia (MYOK), Akorn (AKRX), Spectrum Pharmaceuticals (SPPI), Xencor (XNCR), Cambrex (CBM), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Prestige Brands (PBH), Portola Pharmaceuticals (PTLA), G1 Therapeutics (GTHX), Mirati Therapeutics (MRTX) and Pacira Pharmaceuticals (PCRX).
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 54)
- Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 48)
- Dr. Rajiv Patni, Chief Medical Officer (Age 49)
- Mr. Alfred G. Merriweather, Chief Financial Officer (Age 64)
- Mr. Richard A. King, Chief Operating Officer (Age 53)
Has Adamas Pharmaceuticals been receiving favorable news coverage?
Media stories about ADMS stock have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a daily sentiment score of 0.20 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 46.48 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Adamas Pharmaceuticals.
Who are Adamas Pharmaceuticals' major shareholders?
Adamas Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (8.36%), BlackRock Inc. (6.79%), Macquarie Group Ltd. (4.82%), FMR LLC (3.95%), Janus Henderson Group PLC (3.37%) and Emerald Advisers Inc. PA (2.37%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Rajiv Patni, Richard King, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.
Which major investors are selling Adamas Pharmaceuticals stock?
ADMS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bainco International Investors, Dudley & Shanley Inc., Alps Advisors Inc., Alps Advisors Inc., Oak Ridge Investments LLC, Dupont Capital Management Corp and Hartwell J M Limited Partnership. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Insider Buying and Selling for Adamas Pharmaceuticals.
Which major investors are buying Adamas Pharmaceuticals stock?
ADMS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Point72 Asset Management L.P., Macquarie Group Ltd., Kornitzer Capital Management Inc. KS, Deltec Asset Management LLC, Fisher Asset Management LLC and Bank of America Corp DE. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.
How do I buy shares of Adamas Pharmaceuticals?
Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of ADMS stock can currently be purchased for approximately $22.43.
How big of a company is Adamas Pharmaceuticals?
Adamas Pharmaceuticals has a market capitalization of $628.10 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.
How can I contact Adamas Pharmaceuticals?
Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]
MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
